Search
Displaying 161–170 of 735 for “retinitis clinical trial”
-
Acucela Enrolling Patients in Phase 3 Trial for Stargardt Disease Treatment
Research NewsThe Seattle biotech Acucela is now enrolling participants in its Phase 3 clinical trial for emixustat hydrochloride, an emerging oral drug for slowing vision loss in people with Stargardt disease, an inherited form of a macular degeneration.
-
AGTC Plans Further Clinical Development of Achromatopsia (CNGB3) Gene Therapy
Research NewsInterim results for pediatric patients with CNGB3 mutations were encouraging
-
Vision Improvements Reported in Early Stem Cell Trial for Wet AMD
Research NewsTwo patients with advanced wet age-related macular degeneration (AMD) in a Phase I clinical trial demonstrated improved visual acuity sustained for one year after a sheet of retinal pigment epithelial (RPE) cells derived from embryonic stem cells was transplanted under their retinas. Each patient had one eye treated. Vision improvement for one patient was 29 letters or about 6 lines on an eye chart. The other had a gain of 21 letters or about 4 lines.
-
Iveric Bio’s Therapy Slows Retinal Degeneration in Phase 2b Trial for Dry AMD
Research NewsZimura inhibits a complement protein known as C5, a component of the immune system that, when overactive, can cause retinal degeneration.
-
Ophthotech is Advancing an Impressive Portfolio of Cutting-Edge Therapies for Retinal Diseases
Research NewsThe company is taking on a multi-track strategy that includes retinal gene-therapy development, including delivery of over-sized genes and design of a two-step process of gene knockdown and replacement for autosomal dominant conditions.
-
Disease
Often diagnosed in childhood or adolescence, retinitis pigmentosa (RP) is an inherited retinal disease causing progressive loss of night and peripheral vision. The condition often leads to legal and sometimes complete blindness.
-
Dr. Eliot Berson, Pioneer in Vitamin A Therapy for Retinitis Pigmentosa, Passes Away
Research NewsDr. Berson dedicated himself to clinical care and vision-saving research for people with inherited retinal diseases for five decades.
-
Research News
The company plans to enroll additional patients as young as four years old
-
The Foundation's Investments Are Filling the Pipeline for Vision-Saving Therapies
Research NewsIn addition to funding promising biotech start-ups, the Foundation Fighting Blindness has played a critical role in developing research talent.
